Lower doses may be reasonable for some patients, but microdosing is still off-label, and the strongest evidence still comes from standard therapeutic dosing in populations with clinical obesity or metabolic disease, and many of the broader claims around low-dose use exceed what the evidence supports
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities
First injection should be administered by a healthcare professional
When I prescribe GLP-1 receptor agonists, I gradually increase the dose based on tolerability
Mielgo-Ayuso J, Barrenechea L, Alcorta P, Larrarte E, Margareto J, Labayen I